Research Solutions, Inc. (RSSS) director Chad Cooper, Acquires $3600 in Stock; Iguana Healthcare Management Raised Its Cymabay Therapeutics (CBAY) Stake

The director of Research Solutions Inc, Chad Cooper is in the stock market news today. It was revealed in a public report filled by Chad Cooper and submitted to the SEC on February 26, 2018, he bought 3,000 shares from the firm having a total value of $3,600 U.S. Dollars. The shares average price was $1.2. Chad is trying to increase his company’s share, same as he did in the last month. He purchased another 10,783 shares worth $12,939 USD. Right now, Chad Cooper owns 390,783 shares which are equivalent to about 1.62% of Research Solutions Inc’s market cap.

Iguana Healthcare Management Llc increased Cymabay Therapeutics Inc (CBAY) stake by 138.1% reported in 2017Q3 SEC filing. Iguana Healthcare Management Llc acquired 145,000 shares as Cymabay Therapeutics Inc (CBAY)’s stock rose 21.05%. The Iguana Healthcare Management Llc holds 250,000 shares with $2.02 million value, up from 105,000 last quarter. Cymabay Therapeutics Inc now has $810.63M valuation. The stock decreased 0.48% or $0.07 during the last trading session, reaching $14.62. About 530,691 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 27, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Research Solutions, Inc., through its subsidiaries, provides annual licenses that allow clients to access and utilize features of cloud based software-as-a-service research intelligence platform. The company has market cap of $29.22 million. The firm is also involved in the transactional sale of published scientific, technical, and medical content managed, sourced, and delivered through the Transactions platform. It currently has negative earnings. The Company’s solutions enable life science and other research intensive organizations to speed up research and development activities with single sourced access and management of content and data used in the intellectual property development lifecycle.

The stock 0.31% or $0 during the last trading session, reaching $1.21. It is down 0.00% since February 27, 2017 and is . It has underperformed by 16.70% the S&P500.

Iguana Healthcare Management Llc decreased Merus N V stake by 35,000 shares to 140,000 valued at $2.78 million in 2017Q3. It also reduced Avexis Inc stake by 12,500 shares and now owns 17,500 shares. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) was reduced too.

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 11 by Piper Jaffray. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Wednesday, March 30 by H.C. Wainwright. The firm earned “Overweight” rating on Tuesday, July 21 by Piper Jaffray. The firm has “Buy” rating by Piper Jaffray given on Wednesday, January 31. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25. The firm earned “Buy” rating on Tuesday, September 19 by Cantor Fitzgerald. The firm has “Buy” rating given on Tuesday, November 28 by Leerink Swann. On Monday, July 17 the stock rating was maintained by Piper Jaffray with “Buy”. On Wednesday, January 4 the stock rating was maintained by H.C. Wainwright with “Neutral”. As per Wednesday, January 24, the company rating was maintained by H.C. Wainwright.